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Circulating miRNA signatures of early
pregnancy in cattle
Jason Ioannidis and F. Xavier Donadeu*
Abstract
Background: Low fertility remains a leading cause of poor productivity in dairy cattle. In this context, there is
significant interest in developing novel tools for accurate early diagnosis of pregnancy. MicroRNAs (miRNAs) are
short RNA molecules which are critically involved in regulating gene expression during both health and disease.
MiRNAs have been shown to regulate ovarian function, uterine receptivity, embryonic development and placental
function. Circulating miRNAs can provide useful biomarkers of tissue function and disease; importantly, differential
miRNA profiles have been linked to pregnancy and preeclampsia in humans. This study sought to establish the
potential of circulating miRNAs as biomarkers of early pregnancy in cattle.
Results: We applied Illumina small-RNA sequencing to profile miRNAs in plasma samples collected from eight non-
pregnant heifers on Days 0, 8 and 16 of the oestrous cycle and 11 heifers on Days 16 and 24 of pregnancy. We
sequenced a total of 46 samples and generated 9.2 million miRNA reads per sample. There were no differences in
miRNA read abundance between any of the pregnant and non-pregnant time-points (FDR > 0.1). As a complementary
approach, we analysed sample pools (3–4 samples/pool) corresponding to Days 0, 8 and 16 of the oestrous cycle and
Day 24 of pregnancy (n = 3 pools/group) using Qiagen PCR arrays. A total of 16 miRNAs were differentially expressed
(FDR < 0.1) in plasma between pregnant and non-pregnant animals. RT-qPCR validation using the same plasma
samples confirmed that miR-26a was differentially upregulated on Day 16 pregnant relative to non-pregnant heifers
(1.7-fold; P = 0.043), whereas miR-1249 tended to be upregulated in Day 16 pregnant heifers (1.6-fold; P = 0.081).
Further validation in an independent group of heifers confirmed an increase in plasma miR-26a levels during early
pregnancy, which was significant only on Day 24 (2.0-fold; P = 0.027).
Conclusions: Through genome-wide analyses we have successfully profiled plasma miRNA populations associated
with early pregnancy in cattle. We have identified miR-26a as a potential circulating biomarker of early pregnancy.
Keywords: microRNA, Circulating, Biomarker, Early pregnancy, Bovine, miRNA sequencing, PCR array
Background
As of December 2014, there were approximately 9.7
million cattle in the UK [1]. It is estimated that low fer-
tility and suboptimal management of dairy herds cost
£500 million in lost productivity annually [2, 3]. This
problem is currently maintained by the chronic selec-
tion and use of high-yielding dairy cows. Profitable milk
production depends on regular calving, the target being
that every cow produces one calf a year. An important
limitation to meeting this target is that, although con-
ception rates remain very low (less than 50 % at first
service), tools for accurate early detection of pregnancy
(within 3 weeks) are not available leading to prolonged
inter-calving intervals and significant losses in milk
production. In light of this, the veterinary and dairy
sectors have a particular interest in the development of
novel biomarkers of early pregnancy.
MicroRNAs (miRNAs) have recently emerged as
promising diagnostic biomarkers with high clinical po-
tential. MiRNAs are short, non-coding RNA molecules
which are centrally involved in post-transcriptional con-
trol of gene expression [4]. Different roles of miRNAs in
the reproductive system have been proposed including
the development of ovarian follicles and the corpus
luteum [5, 6], uterine cyclicity and establishment of
pregnancy, and embryonic development [7–10]. In the
early developing bovine conceptus, the levels of some
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miRNAs including miR-496 and miR-125a vary greatly
suggesting a role in the maternal-to-zygotic transcrip-
tional transition [11]. Furthermore, several miRNAs
including miR-27a and miR-92b are differentially
expressed during the development of the placenta, where
they have been associated with trophoblast differenti-
ation and vascularisation [12, 13]. Finally, let-7 and miR-
125b among other miRNAs have been shown to control
mammary gland development and lactation [14].
MiRNAs are naturally secreted from cells into body
fluids where they remain in relatively stable protein or
lipid complexes and can be easily quantified [15–18].
This, combined with the fact that some miRNAs are tis-
sue or developmental stage specific presents the oppor-
tunity to use miRNAs as non-invasive biomarkers of
tissue function associated with a variety of physiological
states (e.g. pregnancy) and diseases (e.g. neoplasia, car-
diovascular disease, osteoarthritis, sepsis) [19, 20]. In-
deed, miRNA-based platforms are currently being used
for clinical diagnosis of various types of human cancer
[19, 20]. Despite this, there are still limitations associated
with measurement of circulating miRNA levels using
existing technologies, which are derived from the pres-
ence of enzymatic inhibitors in serum and plasma, the
low RNA content in bio-fluids, haemolysis and other cell
contamination, and the need for unbiased procedures
for normalisation of miRNA expression data [15, 21].
There is promising evidence of the potential of miR-
NAs as biomarkers of pregnancy. The circulating levels
of miRNAs belonging to the primate- and placenta-
specific C19MC cluster increase with gestational age,
while levels of C14MC cluster miRNAs increase in the
first trimester and decrease in later pregnancy [22, 23].
Furthermore, the C19MC cluster miRNAs, miR-516-5p,
miR-518b, miR-520a and miR-525, are detectable in the
human maternal circulation as early as 12 weeks of ges-
tation [24]. In addition, the circulating levels of some
C19MC miRNAs are significantly correlated with pla-
cental weight [25], consistent with their secretion from
the developing placenta. Recent studies in humans have
also identified miR-141 and miR-149 as pregnancy-
associated circulating miRNAs; circulating levels of miR-
141 significantly increase during gestation whereas the
levels of both miRNAs decrease after delivery [26]. In
sheep, miR-30c, miR-132, miR-379, miR-199a-3p and
miR-320 are differentially expressed in serum on Days
30 or 60 of pregnancy [27]. There is limited information
on pregnancy-related miRNAs in livestock and, to our
knowledge, the levels of circulating miRNAs during early
pregnancy have not been previously published for any
domestic species.
The aim of this study was to profile miRNA levels in
the plasma of cattle during Days 16 and 24 of pregnancy
and to identify miRNA signatures that could be
potentially used for diagnosis of early pregnancy. We
present miRNA profiling results generated using two in-
dependent approaches, Illumina small-RNA sequencing
and Qiagen PCR array.
Results and Discussion
Optimisation of bovine plasma miRNA profiling
We deemed it important to introduce sample quality
control measures and optimise our quantification meth-
odology before proceeding with profiling miRNAs in the
bovine circulation, in order to address common prob-
lems in circulating miRNA quantification which might
bias our study, such as low RNA yields, enzymatic inhib-
ition and haemolysis.
We tested three different commercial kits for extrac-
tion of RNA from bovine plasma, namely, miRNeasy
mini (Qiagen, Netherlands), miRNeasy plasma (Qiagen),
and TRIzol LS (Life Technologies, United Kingdom).
Using 200 μL of bovine plasma, the TRIzol LS protocol
was more efficient than the column-based kits as deter-
mined by RT-qPCR quantification of spiked-in exogen-
ous cel-miR-39-3p (Fig. 1a). An added advantage of the
TRIzol LS protocol is that it allows scaling-up the ex-
traction volume; for our experiments we decided to use
1.05 mL of bovine plasma which yielded a mean of 9.5 ±
0.8 ng of RNA (Fig. 1b). This yield is similar to that re-
ported for bovine plasma in another study (8.6 ng/mL),
but lower than the mean yield reported for human
plasma (25 ng/mL) [22, 28].
The presence of high levels of enzyme inhibitors in
plasma samples (for example, immunoglobulin G) can
significantly reduce the efficiency of RT-qPCR [29]. To
address this, we tested different input RNA volumes and
determined that using 2 μL of RNA extract in a 10 μL
cDNA synthesis reaction yielded the highest reaction ef-
ficiency (Fig. 1c).
Another significant problem in plasma miRNA profil-
ing is red blood cell contamination. As high levels of red
blood cell-derived miRNAs such as miR-451 are associ-
ated with haemolysis [30, 31], the ΔCq between miR-451
and miR-23a has been proposed as a useful indicator of
haemolysis [32]. We confirmed the validity of this ap-
proach for bovine samples by showing good correlation
between the ratio of miR-451 and miR-23a and optical
densities at 414 nm (Additional file 1, A-B). Based on
this, we concluded that all samples used for miRNA pro-
filing were within the normal range for non-haemolysed
bovine plasma (Additional file 1, C-D).
Illumina small-RNA sequencing of bovine plasma
We sequenced a total of 46 small RNA libraries gener-
ated from plasma samples collected from eight non-
pregnant animals (on each of Days 0, 8 and 16 of the
oestrous cycle), and 11 animals on each of Days 16 and
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24 of pregnancy (encompassing the period for which a
pregnancy biomarker would be desired [33]).
We obtained a median of 9.2 million raw sequencing
reads from each sample (Table 1). A length distribution
plot of reads post-trimming showed a distinct peak at
20–23 nucleotides indicating the majority of reads corre-
sponded to mature miRNAs (Fig. 2a). After removal of
low-quality reads, a median of 4 million reads (43.5 % of
total reads) from each sample were mapped to the bo-
vine genome, 68 % of which (2.7 million) were identified
as miRNAs (Table 1). The remaining mapped reads cor-
responded to non-coding regulatory and structural small
RNAs including Y-RNAs and spliceosomal RNAs, and
fragments of larger RNA species such as mRNAs
(Fig. 2b). The vast majority of miRNA reads (99.8 %)
corresponded to registered bovine sequences in miR-
Base; the remaining corresponded to human miRNA ho-
mologues (0.11 %) or to predicted novel miRNAs
(0.06 %, Fig. 2b). The percentage of miRNA reads ob-
tained over the total sequencing reads (30.4 %) was
higher than that reported from sequencing of bovine
plasma in another study (5 %) but lower than obtained
from human plasma using the same sequencing platform
(57.7 %) [22, 34].
Overall, a total of 386 unique miRNAs across all indi-
vidual samples (328 bovine, 37 human and 21 predicted
novel) had more than 10 read counts. On average, the
10 most abundant miRNAs accounted for 61 % of the
total miRNA reads in each sample (Fig. 2c). Out of the
most abundant miRNAs in bovine plasma, miR-486 and
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Fig. 1 Optimisation of methodology for profiling miRNAs in bovine plasma. a RT-qPCR data plots (with mean ± SEM) showing abundance of the
exogenous miRNA, cel-miR-39-3p, in plasma samples after RNA extraction using 3 different kits as indicated. b RNA yield from 1.05 mL bovine
plasma samples using TRIzol LS. c Results of RT-qPCR quantification of miR-451 in plasma (mean ± SEM) using different RNA volumes for reverse-
transcription; highest reaction efficiency was obtained using 2 μL of RNA in a 10 μL cDNA synthesis reaction
Table 1 Summary of results from small-RNA sequencing analyses
NP P16 P24 All
Total sequence reads 9.1 (8.8-9.6) 9.4 (8.7–11.6) 9.9 (8.8–10.7) 9.2 (8.7–10.5)
Reads with adapter 8.0 (7.7–8.9) 8.7 (7.7–10.6) 9.3 (8.0–9.8) 8.3 (7.7–9.6)
Reads which passed QC 4.5 (3.5–5.4) 4.0 (3.3–5.3) 4.0 (2.9–5.6) 4.2 (3.4–5.4)
Reads mapping to genome 4.3 (3.3–5.2) 3.7 (3.1–4.9) 3.6 (2.6–5.4) 4.0 (3.2–5.2)
Total miRNA reads 3.2 (2.2–3.8) 2.2 (2.1–3.0) 2.6 (1.5–3.5) 2.8 (2.1–3.5)
Median (in millions) and 25 % - 75 % percentile (in brackets) values obtained from a total of 46 plasma samples from non-pregnant heifers (NP; Days 0, 8 and 16
after oestrus combined; n = 24) and heifers on Days 16 (P16) and 24 (P24) of pregnancy (n = 11)
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miR-92a are reportedly expressed primarily in erythro-
cytes, and miR-191 is expressed primarily in platelets
[31, 35]. Almost half (40 %) of the 10 most abundant
miRNAs were also identified as highly abundant in bo-
vine plasma in another study whereas 20 % were very
abundant in human plasma [22, 28]. Common miRNAs
identified across studies include miR-486, miR-92a, miR-
192 and miR-423-5p.
One sample from Day 16 of pregnancy was removed
prior to differential expression analysis because it dis-
tinctly had very low total reads per million mapped
(RPMMs). Different comparisons of miRNA expression
data between non-pregnant (NP) and pregnant groups
(P) were made involving 1) the average expression over
Days 0, 8 and 16 of the oestrous cycle (NP; n = 8) for the
non-pregnant group vs each of Day 16 and Day 24 of
pregnancy (P16 and P24; n = 10 and 11, respectively)
and 2) a direct comparison between Day 16 of the
oestrus cycle (NP16) and Day 16 of pregnancy. Principal
component analysis based on these comparisons re-
vealed no clear separation according to pregnancy status
(Fig. 3a). Changes in the levels of 178 individual miRNAs
which passed our quality filters (see Methods) were
determined for each comparison (Additional file 2). Dif-
ferences in the expression of a limited number of indi-
vidual miRNAs were detected although they were
generally small (under 2.5-fold) and not significant after
FDR adjustment (Fig. 3b-d; Table 2). For one of the miR-
NAs, miR-133a, levels were up to 7.4-fold lower in Day
16 pregnant relative to non-pregnant heifers (FDR =
0.127) although the miRNA was not detectable by qPCR
and thus those differences could not be validated
further.
Bovine plasma miRNA profiling using Qiagen PCR arrays
To complement our sequencing analyses we used a
commercial Custom PCR array platform to profile the
expression of 308 unique bovine miRNAs in the same
plasma samples. As it is not feasible to screen a large
number of samples using PCR arrays, we analysed 3
sample pools (3–4 samples/pool) from each of Days 0, 8
and 16 from non-pregnant heifers and from Day 24
pregnant heifers (we reasoned we would more easily find
differences in miRNA expression at Day 24 than at Day
16 of pregnancy).
We detected a total of 208 miRNAs in bovine plasma
(based on mean Cq < 35 across all sample pools; Fig. 4a),
the most abundant of which (Fig. 4b) corresponded to
miRNAs reportedly expressed at high levels in blood
cells including erythrocytes (miR-451, miR-486, miR-16),
leukocytes (miR-150, miR-27a, miR-23a) and thrombo-
cytes (miR-223, miR-20a, miR-24), and which are puta-
tively released into the plasma through apoptosis, lysis
or active secretion [36–38]. The absence of detectable
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Fig. 2 Summary of small-RNA sequencing read count data. a Length distribution (mean ± SEM) of read counts (after trimming) from Illumina
sequencing of bovine plasma samples (nt = nucleotides). b Relative abundance of different RNA species sequenced in bovine plasma. c Top
20 miRNAs in bovine plasma detected by Illumina small-RNA sequencing; mean percentages of the total miRNA reads per million mapped
(RPMMs) are shown
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haemolysis in our samples (see above) indicates the de-
tected blood cell miRNAs are predominantly the result
of secretion/activation and not cell lysis.
Comparing the 20 most abundant miRNAs in each of
the PCR array and sequencing datasets, only 6 miRNAs
(miR-486, miR-22-3p, miR-191, miR-92a, miR-140 and
miR-451) were common. A very abundant miRNA in the
sequencing dataset (miR-21-5p) could not be compared
as it was not included in the PCR array. The overall poor
agreement in abundant miRNAs identified by the two
techniques can in part be explained by platform-specific
biases such as those associated with sequencing adaptor
ligation and differences in primer-specific PCR effi-
ciency, which are known to affect the representation
of miRNAs in a library therefore changing the per-
ceived order of abundance of the miRNAs within a
sample [39–41].
As before, differential expression analyses for each
miRNA was performed considering the average expres-
sion value over Days 0, 8 and 16 of the oestrous cycle
for the non-pregnant group (NP). Principal component
analysis of PCR array results showed a clear separation
between NP and P24 groups (Fig. 5a). Of the 176 unique
miRNAs included in the analysis (after excluding low
abundance miRNAs; see Methods), a total of 16 miRNAs
were differentially expressed between the two groups
(FDR < 0.1), 8 of which at ≥ 2-fold (Fig. 5b-c; Table 3;
Additional file 3).
Generally, we observed poor overlap between differen-
tially expressed gene lists from the two high-throughput
datasets. Thus, only four of all miRNAs differentially
expressed (P < 0.05) between pregnant (Day 24) and
non-pregnant animals in the PCR array, i.e. miR-99b,
miR-152, miR-101, miR-103, were also different (P <
0.05) between pregnant and non-pregnant groups (all
comparisons) in the sequencing dataset. In some cases,
the poor overlap was due to the miRNAs being under-
represented in the sequencing libraries (e.g. miR-29c,
miR-1249) resulting in low-confidence profiles. Other
miRNAs such as miR-4532 were not included in the
PCR arrays, therefore cross-platform validation was not
possible. Platform-specific biases (indicated above) and
the fact that pooled rather than individual samples were
used in the PCR arrays may have also contributed to the
relative lack of agreement between sequencing and PCR
arrays. Taken together, our results highlight the
Fig. 3 Results of differential expression analysis of miRNA sequencing data. a PCA plot using data from all pregnant (P16 and P24) and non-
pregnant (NP) time-points obtained by Illumina small-RNA sequencing. Scatterplots for P16 vs NP16 (b) P16 vs NP (c) and P24 vs NP (d)
comparisons using individual miRNA data are shown. The grey dotted lines indicate the 2-fold change threshold, and miRNAs which
changed more than 2-fold between groups have been labelled. All data have been log2 transformed
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limitations of current circulating miRNA profiling tech-
nologies, especially when subtle differences in gene ex-
pression are investigated, such as here, and show the
importance of cross-platform validation.
RT-qPCR validation of high-throughput data
From the results of PCR array and small-RNA sequen-
cing we selected (based on both fold-change and P
value) a total of 21 differences in miRNA abundance (in-
volving 17 unique miRNAs) for validation by RT-qPCR
(Additional file 4). Since we did not want our selection
of miRNA candidates to be constrained by the limited
number of differences originally obtained after FDR ad-
justment (FDR < 0.1; Tables 2 and 3), in the validation
analyses we included 13 differences which were signifi-
cant (P < 0.05) only before FDR adjustment. Because Day
16 of pregnancy was not included in the PCR array ana-
lyses (from where a majority of differences for validation
were obtained), for the sake of inclusiveness both P16
and P24 were included in all validation analyses.
We could robustly quantify 15 individual miRNAs by
RT-qPCR representing a total of 17 differences in
miRNA abundance between pregnant and non-pregnant
groups. For 9 of these differences (Fig. 6a) the results of
qPCR were consistent with those obtained by PCR array
or sequencing although significance was only obtained
for miR-26a; an increase in the levels of this miRNA was
significant on Day 16 (NP vs P16, 1.7 fold, P = 0.043) but
not on Day 24 (1.7 fold, P = 0.208 Fig. 6b). A trend for
an increase in miR-1249 levels on Day 16 of pregnancy
was also identified but was not statistically significant
(NP vs P16, P = 0.081; Fig. 6b). To more robustly valid-
ate the changes in miR-26a during early pregnancy, par-
ticularly as they were relatively small, we analysed
plasma samples from a different, larger group of heifers
during early pregnancy (Fig. 6c). In this group of
Table 2 Changes in circulating miRNA abundance identified by
small RNA sequencing
Comparison Fold change P value
bta-miR-101 NP16 vs P16 0.78 0.045
bta-miR-25 NP16 vs P16 0.81 0.014
bta-miR-19a NP16 vs P16 1.22 0.029
bta-miR-130b NP16 vs P16 1.33 0.019
bta-miR-328 NP16 vs P16 1.34 0.006
bta-miR-301b NP16 vs P16 1.49 0.045
hsa-miR-4532 NP16 vs P16 2.21 0.006
bta-miR-133a NP vs P16 0.14 0.001
bta-miR-193b NP vs P16 0.74 0.021
bta-miR-365-3p NP vs P16 0.75 0.026
bta-miR-2957 NP vs P16 0.77 0.048
bta-miR-152 NP vs P16 0.77 0.048
bta-miR-107 NP vs P16 0.82 0.036
bta-miR-103 NP vs P16 0.83 0.037
bta-miR-328 NP vs P16 1.22 0.003
bta-miR-133a NP vs P24 0.42 0.028
bta-miR-125b NP vs P24 0.71 0.024
bta-miR-99a-5p NP vs P24 0.72 0.016
bta-miR-365-3p NP vs P24 0.74 0.013
bta-miR-99b NP vs P24 0.77 0.022
bta-miR-10b NP vs P24 0.84 0.037
List of plasma miRNAs with different abundance between pregnant and non-
pregnant heifers (NP16 vs P16, NP vs P16 and NP vs P24 comparisons) based
on RPMM values from Illumina sequencing. Fold change in pregnant relative
to non-pregnant heifers are shown. FDR > 0.1 for all miRNAs
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animals, when compared to levels before insemination,
plasma levels of miR-26a were higher on Day 24 of preg-
nancy (2.0-fold; P = 0.027). On average, miR-26a levels
were also higher on Day 16 (1.7-fold) although this dif-
ference did not reach significance (P = 0.118). Thus,
from analyses in two independent groups of animals we
concluded that the levels of miR-26a increase during
early pregnancy in heifers.
Although expressed ubiquitously, distinctly high
levels of miR-26a have been reported in the embryo,
the ovary, and immune-related tissues and cells such as
the thymus and B/T cells of different species [42–45].
Interestingly, miR-26a has been shown to directly
down-regulate IFN-β, a major cytokine involved in in-
nate and adaptive immune responses, suggesting a po-
tential role for this miRNA as an immuno-suppressor
during early pregnancy [46]. Additionally, recent stud-
ies in pig and goat have reported increasing levels of
miR-26a in the conceptus and the ovary as early as Day
20 of pregnancy [47, 48]. Also, high plasma miR-26a
levels have been associated with pre-eclampsia in
humans [49]. These findings support the notion that
miR-26a is involved in pregnancy, possibly by exerting
immunomodulatory effects. Further studies should in-
vestigate the precise origin and function of this miRNA
during pregnancy.
Mir-1249, identified by PCR array analyses as differen-
tially expressed in pregnant animals, was severely under-
represented in our sequencing library, with only 6.1
counts per million on average, which prevented any con-
clusions about its expression in bovine plasma. This may
be the result of sequence- and secondary structure-
dependent ligation biases during library preparation, a
common issue with next-generation sequencing tech-
nology which affects all samples equally and thus is
not considered to bias differential expression analyses
[39–41]. The case of miR-1249 is a good example of
the need to use different quantification methods for
cross-platform validation of results. The levels of miR-
1249 in granulosa cells have been shown to vary during
follicle development in bovine [50], and miR-1249 ex-
pression has been confirmed in bovine mammary
Fig. 5 Differential expression analysis using PCR array data. a PCA plot and b scatterplot of individual miRNA data (NP vs P24). The grey dotted lines in
b) indicate the 2-fold change threshold, and the highlighted data-points (in red) represent FDR < 0.1. The data have been log2 transformed. c Volcano
plot for the same data shown in (b). The horizontal dotted orange line indicates the significance threshold (P = 0.05) and the vertical grey lines indicate
the 2-fold change threshold. Data-points representing differences with FDR < 0.1 have been highlighted in red. The data have been log2 transformed
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glands, however little is known about its expression
and functions in other tissues [51].
The fact that results of RT-qPCR and high-throughput
analyses agreed (i.e. differences between pregnant and
non-pregnant groups showed the same trend) for only 9
of the 17 differences in miRNA abundance analysed may
have been due in part to the intrinsically very low levels
of RNA contained in plasma; this, together with the
presence of several inhibitors of RT-qPCR enzymes in
plasma make accurate quantification particularly chal-
lenging, especially when differences between the experi-
mental groups being compared are small. Added to
these are platform-specific biases and intrinsic inter-
animal variation. In the case of the PCR arrays, the use
of pooled samples may also have contributed to dis-
agreement in the results from different profiling plat-
forms. A recent study reported a 54.6 % agreement in
human liver and brain tissue miRNA profiles across
RT-qPCR, microarrays and small-RNA sequencing plat-
forms [52], which is comparable to the agreement re-
ported in our study. This most likely reflects the
limitations associated with quantification of plasma
miRNAs discussed above. Finally, we only attempted to
validate a fraction of the differences identified in the
PCR array and sequencing experiments; further valid-
ation analyses may identify additional potential miRNA
biomarkers of early pregnancy.
Conclusions
Through RNA sequencing and qPCR profiling in cattle,
we identified for the first time changes in the levels of
miRNAs in plasma during early pregnancy. Specifically,
we identified an increase (up to 2-fold) in the levels of
miR-26a during Days 16 to 24 of pregnancy. These
changes putatively reflect changes in miRNA expression
in one or more body tissues and may play potentially
important roles in the establishment of pregnancy. Over-
all, the differences in plasma miRNAs levels between
pregnant and non-pregnant animals were small; larger
differences in circulating miRNAs may occur at later
stages of pregnancy. In addition, a limited ability to ac-
curately quantify low abundance RNAs using available
technologies may have prevented detecting larger differ-
ences in miRNA levels during early pregnancy. In sum-
mary, our results identify miR-26a as a novel candidate
biomarker of early pregnancy in cattle.
Methods
Experimental design and sample collection
During March-April of 2013, 24 cycling Holstein-Friesian
heifers (14–17 months old) were oestrus-synchronised
using Eazi-Breed™ CIDR® Cattle Insert (1.38 g progester-
one over 8 days; Zoetis, USA), Receptal® (0.02 mg busere-
lin on the day of CIDR insertion; MSD Animal Health,
UK) and Estrumate® (0.5 mg cloprostenol 7 days after
CIDR insertion; MSD Animal Health). After 48 h (Day 0)
animals were either sham-inseminated (non-pregnant
group; n = 8) or inseminated with frozen semen (pregnant
group; n = 16). Animals were inseminated or sham-
inseminated again 24 h later. Blood was collected on Days
0, 8, 16 from all animals. Additional samples were col-
lected on Day 24 from the pregnant group. Pregnancy was
confirmed twice on Day 35 and Day 60 by trans-rectal
ultrasound. Five animals failed to become pregnant after
insemination and were excluded from the study.
Blood was collected from all animals in 4 × 10 mL K2
EDTAVacutainer tubes (Becton Dickinson, USA) by jugu-
lar venepuncture, using 18G needles (Becton Dickinson),
and stored at 4 °C. Within 2 h of collection samples were
centrifuged at 1,900 × g for 10 min at 4 °C to remove
blood cells, and then again at 16,000 × g for 10 min at 4 °C
to remove cellular debris and platelets. All plasma samples
were immediately frozen at −80 °C. All heifers used in this
study were kept under the same housing and feeding con-
ditions in a single farm and all animal procedures were
carried out under the UK Home Office Animals (Scientific
Procedures) Act 1986 with approval by the Ethical Review
Committee, University of Edinburgh.
RNA extraction
RNA was extracted from 1.05 mL of plasma using
TRIzol LS (Life Technologies, USA), following the
Table 3 Differences in circulating miRNA abundance identified
by PCR array analyses
Fold change P value FDR
bta-miR-101 0.46 0.007 0.090
bta-miR-141 0.55 0.002 0.058
bta-miR-29c 0.65 0.005 0.083
bta-miR-339a 0.66 0.006 0.088
bta-miR-29a 0.69 0.001 0.034
bta-miR-103 1.65 0.008 0.092
bta-miR-26a 1.76 0.000 0.016
bta-miR-30b-5p 1.78 0.003 0.064
bta-miR-26b 1.91 0.005 0.083
bta-miR-631 2.07 0.008 0.092
bta-miR-374b 2.20 0.000 0.016
bta-miR-151-5p 2.35 0.003 0.064
bta-let-7d 2.42 0.005 0.083
bta-miR-30c 2.63 0.000 0.016
bta-let-7f 2.76 0.000 0.016
bta-miR-454 2.83 0.008 0.092
List of differentially expressed miRNAs on Day 24 of pregnancy (NP vs P24;
FDR < 0.1) based on Qiagen PCR array expression data. Fold changes were
calculated as pregnant/non-pregnant
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manufacturer’s protocol. During the RNA extraction
protocol, glycogen (180 μg; Sigma-Aldrich, USA) was
added to each sample to facilitate visualisation of pre-
cipitated RNA, and an exogenous miRNA control,
syn-cel-miR-39-3p (0.25 fmol; Qiagen, NL), was
spiked-in to each sample. RNA was re-suspended in
30 μL of RNase-free water and used immediately or
frozen at −80 °C.
Illumina small-RNA sequencing and data analysis
Small-RNA libraries were prepared using the Illumina
TruSeq small-RNA sample preparation kit (Illumina,
USA) following the manufacturer’s protocol. Libraries
were submitted to 36-base single-end sequencing using
the Illumina HiSeq 2000 platform. Raw sequencing data
were processed using the sRNAtoolbox software [53].
The bovine genome (UMD 3.1) was used as reference;
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Fig. 6 Results of RT-qPCR validation of high-throughput analyses data. a Comparative fold-changes (mean ± SEM) in miRNA abundance between
pregnant and non-pregnant groups obtained by high-throughput analyses (PCR array or sequencing) and RT-qPCR. Results to the left and right
of the dotted line correspond to NP16 vs P16 and NP vs P24 comparisons, respectively (Additional file 4). b RT-qPCR data plots (with mean ± SEM) for
selected comparisons between pregnant and non-pregnant groups including the two differences in miRNA abundance that were significant (miR-26a,
* indicates P < 0.05) or tended to be significant (miR-1249, NP vs P16, P < 0.1). c RT-qPCR data plots (with mean ± SEM) obtained from an independent
group of heifers and which confirms an increase in plasma miR-26a levels during early pregnancy. NP corresponds to plasma samples collected before
insemination (Day 0) from the same animals
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trimmed and quality-controlled reads were mapped
against bovine (primarily) and human (for homologue
identification) mature miRNAs from miRBase (accessed
11/06/2014; [54]) allowing only one-nucleotide mis-
matches. After mapping, human and bovine miRNA
read counts were merged and normalised to generate
reads per million mapped (RPMM). MiRNAs detected
with less than 25 RPMMs in more than 75 % of the sam-
ples in each of the experimental groups were excluded,
keeping 178 miRNAs for further analysis. The average
within-animal expression of each miRNA in the non-
pregnant group was calculated (mean of Days 0, 8 and
16) and used for further analyses (NP group). Normal-
ised expression levels (RPMMs) were log2 transformed
before applying two-sample t-tests on the data, followed
by an FDR adjustment of the P values using R program-
ming. The transformed data were normally distributed
as determined by the D’Agostino-Pearson omnibus and
Shapiro-Wilk normality tests. Comparisons made were
NP16 vs P16 (a direct comparison between non-
pregnant and pregnant groups on Day 16), NP vs P16
and NP vs P24.
Qiagen custom PCR arrays
We used commercial 384-well Custom PCR arrays
(Qiagen) which covered a total of 377 unique human
miRNAs, 308 of which were conserved in cow (2 nucleo-
tide mismatch allowed). Three pools of 3 to 4 samples
each, from each of Day 0, Day 8 and Day 16 for non-
pregnant animals, and from Day 24 pregnant animals (12
pools in total) were analysed. cDNA (10 μL) was synthe-
sised from 2 μL RNA sample using miScript II RT kit
(Qiagen) in a Whatman-Biometra Thermocycler (Biome-
tra, USA). The arrays were setup according to the manu-
facturer’s instructions and were run on the LightCycler
480 System (Roche, Switzerland). Data analysis was per-
formed using Microsoft Excel and R programming. Raw
Cq data were initially filtered to remove wells with non-
specific amplification as identified by melting-curve ana-
lysis. Next, miRNAs which had Cq > 35 in more than 75 %
of samples per experimental group were removed from
the dataset. Cq-values were normalised using the global
mean expression, which was calculated from the miRNAs
which were detected in all of the sample pools. The mean
expression across non-pregnant time-points (Days 0, 8
and 16) was used for analyses, as for the sequencing data,
resulting in 3 data-points for analyses from each of preg-
nant and non-pregnant groups (NP vs P24). The statistical
analysis of the transformed normalised data was per-
formed as described for the sequencing data above.
RT-qPCR validation of high-throughput data
Results of high-throughput analyses (small-RNA sequen-
cing or PCR arrays) were validated by RT-qPCR on the
same plasma samples used for sequencing (n = 8 heifers/
group). cDNA was generated as described above and di-
luted for use in 10 μL qPCR reactions using Qiagen
SYBR Green kits in an Agilent Mx3005P qPCR system
(Agilent Technologies, USA). Raw fluorescence data
were processed using Agilent MxPro software. A fluores-
cence threshold of 0.1 was set for all experiments. The
amplification efficiency generally ranged between 85 % -
115 %, with R2 > 0.85. Cq-values and gene expression
data were processed using Microsoft Excel and statistical
analysis was performed using GraphPad Prism 6 (Graph-
Pad Software, USA). Specifically, data were log2 trans-
formed and tested for normality as described for the
small-RNA sequencing data, and Dunn’s multiple com-
parison tests (non-parametric) were used to generate P
values for the comparisons of miRNA levels between
non-pregnant (NP) and pregnant groups (P16 or P24).
Validation of early pregnancy miRNA profiles in an
independent group of heifers
During November 2015, 16 cycling, 14–17 month old
Holstein-Friesian heifers were oestrus-synchronised and
inseminated as described above. Blood samples were col-
lected on Days 0 (before insemination), 16 and 24 and
processed for RT-qPCR analysis as described above.
Samples were analysed for 11 animals confirmed preg-
nant on Day 35.
Availability of supporting data
Data sets supporting the results of this article are in-
cluded within the article and its additional files.
Additional files
Additional file 1: Determining haemolysis of bovine plasma samples.
Samples with or without visible haemolysis were analysed to determine
A) the ΔCq between miR-451 and miR-23, and B) optical density at
414 nm (as a measure of oxyhaemoglobin levels). ΔCq (C) and optical
density (D) values for all plasma samples (n = 46) used for small RNA-
sequencing and PCR array profiling, showing the absence of detectable
haemolysis. Mean ± SEM is shown. (PDF 109 kb)
Additional file 2: Small-RNA sequencing data. Normalised expression
data (reads per million mapped) and differential expression analysis
results for bovine plasma miRNAs, generated using small-RNA sequencing.
(XLSX 102 kb)
Additional file 3: PCR array data. Normalised expression data and
differential expression analysis results for bovine plasma miRNAs, generated
using PCR arrays. (XLSX 58 kb)
Additional file 4: Differences in miRNA levels validated by qPCR. List of
differences (P < 0.05) in miRNA abundance obtained by PCR array or
sequencing (NP16 vs P16, NP vs P16 and NP vs P24) that were selected
for validation by RT-qPCR. Fold changes were calculated as pregnant/
non-pregnant. (XLSX 11 kb)
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